Literature DB >> 25115782

Severe agitation in depression precipitated by dasatinib.

Musa Basseer Sami1, Farida Yousaf2, Antonio Fialho1.   

Abstract

We describe a case of a man with chronic myeloid leukaemia who achieved remission through dasatinib therapy after being unable to tolerate several tyrosine kinase inhibitor (TKI) regimens due to severe physical side effects. However, this coincided with the onset of distressing agitation, insomnia and motor restlessness leading him to take a large zopiclone overdose. Start of appropriate therapy with a clonazepam, venlafaxine and mirtazapine combination led to a rapid improvement in symptomatology. We discuss the differential diagnosis and review the literature of neuropsychiatric complications of TKIs. This case serves as an illustrative reminder that in cases of complicated agitation referral to specialist mental health teams for rational psychopharmacological management is advised. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25115782      PMCID: PMC4139561          DOI: 10.1136/bcr-2014-204166

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

Review 1.  Chronic restlessness with antipsychotics.

Authors:  Irene M Bratti; John M Kane; Stephen R Marder
Journal:  Am J Psychiatry       Date:  2007-11       Impact factor: 18.112

2.  Small molecule tyrosine kinase inhibitor and depression.

Authors:  Richard Quek; Jeffrey A Morgan; Suzanne George; James E Butrynski; Kathleen Polson; Fremonta Meyer; George D Demetri; Susan D Block
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

3.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

4.  Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness.

Authors:  Noel Hannan; Zaf Hamzah; Henry Omoniyi Akinpeloye; David Meagher
Journal:  J Psychopharmacol       Date:  2007-03       Impact factor: 4.153

5.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.

Authors:  A Hochhaus; S G O'Brien; F Guilhot; B J Druker; S Branford; L Foroni; J M Goldman; M C Müller; J P Radich; M Rudoltz; M Mone; I Gathmann; T P Hughes; R A Larson
Journal:  Leukemia       Date:  2009-03-12       Impact factor: 11.528

6.  Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.

Authors:  Kristin M Phillips; Javier Pinilla-Ibarz; Eduardo Sotomayor; Morgan R Lee; Heather S L Jim; Brent J Small; Lubomir Sokol; Jeffrey Lancet; Sara Tinsley; Kendra Sweet; Rami Komrokji; Paul B Jacobsen
Journal:  Support Care Cancer       Date:  2012-11-20       Impact factor: 3.603

7.  Onset of improvement and response to mirtazapine in depression: a multicenter naturalistic study of 4771 patients.

Authors:  Francis Lavergne; Ivan Berlin; Alex Gamma; Hans Stassen; Jules Angst
Journal:  Neuropsychiatr Dis Treat       Date:  2005-03       Impact factor: 2.570

  7 in total
  1 in total

Review 1.  The role of dasatinib in the management of chronic myeloid leukemia.

Authors:  Runzhe Chen; Baoan Chen
Journal:  Drug Des Devel Ther       Date:  2015-02-09       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.